Five-year analysis of neoadjuvant dabrafenib and trametinib for stage III melanoma.

已完结 10 由丫丫发布于 2024/7/8 10:08:59

DOI:10.1016/j.annonc.2024.05.002
作者：A M Menzies, S N Lo, R P M Saw, M Gonzalez, S Ch'ng, O E Nieweg, K F Shannon, P M Ferguson, J Lee, L Emmett, R Kapoor, R V Rawson, J R Stretch, J F Thompson, A J Spillane, H Rizos, R A Scolyer, G V Long
文献类型：期刊论文
补充材料：只需要正文

Elsevier

Abstract：BackgroundNeoadjuvant dabrafenib plus trametinib has a high pathological response rate and impressive short-term survival in patients with resectable stage III melanoma. We report 5-year out

应助信息

求助已完结，文件已删除 如有需求请重新发布求助一键发布

感谢使用Book学术
本站所有文献仅供个人学习和参考，请勿将文件进行传播。共同遵守网站规定和相关知识产权规定。

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:其它数据库First-Principles Study on Doping of Copper Halides